Cresco Earnings + Call Notes
U.S. cannabis leader shares Q325 results.
$165M Revs; est. $164.1M
$40M aEBITDA; est. $36.2M
$79M GP; est. $78.3M
$17.8M OI; est. $19.9M
47.9% GM; est. 47.7%
Retained the No. 1 share position in multiple billion dollar market
“In Q3, we refinanced our debt and strengthened our balance sheet while delivering solid results and maintaining leadership across key markets through disciplined execution.
Our proven retail and wholesale capabilities continue to drive profitability, while new dispensaries in Ohio, expansion into Kentucky, and our upcoming product launch in Germany are unlocking compelling avenues for growth. Together, these initiatives position Cresco Labs to outperform the market and create lasting shareholder value.
“The cannabis industry is entering a new phase of growth and consolidation, and Cresco Labs is prepared to lead. Operators with scale, efficiency, and discipline will define the next chapter. By leveraging our core assets and operational excellence, we’re building an emerging growth platform designed to create long-term value, both within and beyond regulated U.S. cannabis.” Charlie Bachtell, Cresco Labs CEO
Call Notes
